Effect of ivermectin on scabies: a retrospective evaluation.

objectiveThis study, aimed at determining the effect of ivermectin on scabies, which has recently reached epidemic proportions, was conducted by the Department of Dermatology and Venereology at Dicle University. The study aims to evaluate the success of ivermectin in the treatment of scabies, identify variables affecting this success, and contribute positively to the development of future national treatment protocols. Additionally, the study seeks to test the hypothesis that ivermectin, which is significantly easier to use in cases of failure with topical treatments, is a good first-line treatment option. MATERIALS AND

methodsIn this retrospective study, 412 patients diagnosed with scabies via clinical examination by a specialist physician and recommended a 200 µg/kg dose of ivermectin at one-week intervals, who presented to Dicle University Dermatology and Venereology Clinic between January 1, 2023, and June 30, 2024, were examined. Fifty-two patients whose records lacked the parameters evaluated in the study were excluded. A total of 360 patients were included in the study. Data on children under five years of age, those weighing less than 15 kg, and pregnant or lactating women were not obtained due to insufficient information regarding oral ivermectin use in these groups. Data were evaluated with SPSS-21.0 statistical program and the value, mean, median value, standard deviation, incidence rate and frequency of each parameter in total patients were recorded. Associations were analysed using Kolmogorov-Smirnov test, dependent t test, Wilcoxon test, Pearson Chi-square (χ2) test, Yates Chi-square (χ2) test, Fisher Chi-square (χ2) test analysis, Mc-Nemar test, Pearson/spearman correlation analysis, logistic regression analysis. A p-value of < 0.05 was considered statistically significant.

resultsThe ivermectin treatments for all 360 patients were prescribed by a specialist physician, and 78.6% (283) of the patients benefited from the treatment. Of these 360 patients, 295 (81.94%) had tried at least one other treatment option before ivermectin and did not benefit from it, while 66.1% (43 out of 65) of those who had not previously undergone treatment benefited from ivermectin. Furthermore, 81.36% (240 out of 295) of patients who did not respond to previous treatments benefited from ivermectin.

conclusionThis study concluded that ivermectin could be a significant treatment option for patients diagnosed with scabies. The superiority of appropriately dosed ivermectin treatment over other treatments was observed, particularly in patients resistant to other scabies treatments.